Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)'s Investigational New Drug (IND) approval of ... Read More